MetaCap

Artiva Biotherapeutics (ARTV) vs Lineage Cell Therapeutics (LCTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Artiva Biotherapeutics (ARTV) has outperformed Lineage Cell Therapeutics (LCTX) over the past year, gaining 20.8% versus a loss of 55.6%. Lineage Cell Therapeutics is the larger company by market cap ($195.3 million vs $186.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARTV+20.77%LCTX-55.64%
+347%+136%-75%
Nov 21, 20251 yearNov 20, 2026
ARTV-68.50%LCTX-22.81%
+101%+2%-97%
Jul 15, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARTV versus LCTX key metrics
MetricARTVLCTX
Share price$3.78$0.7719
Market cap$186.85M$195.26M
1-day change-1.31%-5.87%
YTD return-11.89%-53.78%
1-year return+20.77%-55.64%
5-year return—-61.21%
EPS (TTM)$-2.85$-0.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$14.56M
Revenue growth (YoY)-100.00%+53.24%
Net income (latest FY)$-83.86M$-63.53M
Operating margin—-251.57%
Net margin—-436.47%
52-week high$14.53$1.99
52-week low$2.96$0.77
Distance from 52-week high-73.98%-61.21%
Analyst consensusbuystrong_buy
Avg. price target upside+448.94%+612.53%
Average volume792.26K1.64M
Shares outstanding49.43M252.95M
Employees13472
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARTV has outperformed LCTX by 76.4 percentage points over the past year.
  • Lineage Cell Therapeutics grew revenue faster in its latest fiscal year (+53.24% vs -100.00%).

About Artiva Biotherapeutics

ARTV stock →

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees

About Lineage Cell Therapeutics

LCTX stock →

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 72 employees

ARTV vs LCTX FAQ

Which is bigger, Artiva Biotherapeutics or Lineage Cell Therapeutics?

Lineage Cell Therapeutics (LCTX) is larger, with a market capitalization of $195.26M compared with $186.85M for Artiva Biotherapeutics (ARTV).

Which stock has performed better over the past year, ARTV or LCTX?

ARTV returned +20.77% over the past 12 months, compared with -55.64% for LCTX (price return, excluding dividends). Past performance does not predict future results.

Are Artiva Biotherapeutics and Lineage Cell Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons